Herpes Zoster and Its Prevention

DOI Web Site Web Site 3 Citations 42 References
  • KAMIYA Hitoshi
    National Mie hospital Research Committee on Varicella Vaccine and Herpes Zoster
  • ASANO Yoshizo
    Department of Pediatrics, Fujita Health University Research Committee on Varicella Vaccine and Herpes Zoster
  • SHIRAKI Kimiyasu
    Department of Virology, University of Toyama Research Committee on Varicella Vaccine and Herpes Zoster
  • NAKANO Takashi
    National Mie hospital Research Committee on Varicella Vaccine and Herpes Zoster
  • HIGA Kazuo
    Department of Anesthesiology, Fukuoka University Research Committee on Varicella Vaccine and Herpes Zoster

Bibliographic Information

Other Title
  • 帯状疱疹とその予防に関する考察
  • タイジョウホウシン ト ソノ ヨボウ ニ カンスル コウサツ

Search this article

Abstract

The mean herpes zoster incidence in Japan was 4.15/1,000 person-years and was 5.23-7.84/1,000 person years among those 50 years old and older. One in three persons experiences herpes zoster before age 80, indicating how common it is. The Oka varicella vaccine was developed to prevent varicella in healthy and immunocompromized children and is now used to prevent varicella in 20 million people worldwide. Contact with varicella patients and Oka varicella vaccine are reported to augment varicella-zoster virus immunity in adults and the elderly. Oxman et al. have shown that Oka varicella vaccine prevents herpes zoster and postherpetic neuralgia (PHN) in the elderly. Oka varicella vaccine is approved to prevent herpes zoster and PHN in the elderly in USA and Europe. We review the relationship between varicella/Oka varicella vaccine and herpes zoster, the study by Oxman et al., and the need to introduce this new application of Oka varicella vaccine in Japan.

Journal

  • Kansenshogaku Zasshi

    Kansenshogaku Zasshi 84 (6), 964-701, 2010

    The Japanese Association for Infectious Diseases

Citations (3)*help

See more

References(42)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top